The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Frank Takkinen - Lake Street Capital Markets, LLC - Analyst
: Good morning. Can you guys hear me now?
Question: Frank Takkinen - Lake Street Capital Markets, LLC - Analyst
: I apologize. Maybe just to start on the commercial side on Veris, you mentioned a couple comments. Obviously, there's new leadership there, a
couple new market development managers. Maybe dive a little deeper into what we should expect for commercial investments related to Veris
over the next couple of years or quarters?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 15, 2023 / 1:30PM, PAVM.OQ - Q3 2023 PAVmed Inc Earnings Call
Question: Frank Takkinen - Lake Street Capital Markets, LLC - Analyst
: Yeah, that's good color. And my second question was going to be on the pharma side of the Veris platforms. So maybe I'll continue with that
thought process, maybe talk about when we could see some first partnerships across the goal line? And then I know I heard your comment about
focusing mostly on the post-FTA approval phase. Maybe talk to why you think that's the most logical area of development to focus on? And if there
is still opportunity to work into some of the clinical trials as well on the maybe Phase II or Phase III timeframes.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 15, 2023 / 1:30PM, PAVM.OQ - Q3 2023 PAVmed Inc Earnings Call
Question: Frank Takkinen - Lake Street Capital Markets, LLC - Analyst
: Okay. That's good color. I'll stop there. Thanks for taking the question and congrats on all the progress.
Question: Edward Woo - Ascendiant Capital Markets LLC - Analyst
: Yeah, congratulations on all the progress. You mentioned that for Veris, a big opportunity in the pharma is post-FDA approval. How big of that
opportunity is versus drugs that are in clinical trials?
Question: Edward Woo - Ascendiant Capital Markets LLC - Analyst
: For some of those who are not as familiar, it's typically for drugs that are -- therapeutics that are approved. Is there -- like how intensive is the
monitoring post-FDA approval?
Question: Edward Woo - Ascendiant Capital Markets LLC - Analyst
: Great. Well, thanks for answering my questions and I wish you guys good luck. Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 15, 2023 / 1:30PM, PAVM.OQ - Q3 2023 PAVmed Inc Earnings Call
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Good morning, Dennis. Good morning, Lishan.
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Good. How are you? So, just to follow up on the major academic cancer centers, obviously that sale cycle is probably fairly lengthy. Would it be
accurate to say it's probably somewhere in the 6 to 12 month range? Could it be longer?
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Yeah, and then I know you said a number of centers that you're speaking with. How many total centers are there that you're having conversations
with? And sort of -- is that the -- would you qualify those as part of a qualified pipeline you have, or some of them early stage in various forms,
maybe just a little more color on that.
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay. And then just switching to the device, I think you provided a lot of color on the opportunity to integrate the Veris platform in clinical trials
as well as in the actual post-marketing of these new drugs that are in various stages of coming to market. Maybe just talk about the device itself,
the software, there's always -- we hear obviously always about security breaches and there's a lot of unsecured firms out there trying to prevent
that. Maybe talk about the development of the software, the monitoring, how comfortable do you feel about the security of that and the HIPAA
compliance at this stage, or is that part of the process you're working on at this point.
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Excellent. That's a great color. And then maybe switching just briefly to Lucid, I know you did the call yesterday. You have a new revenue cycle
management firm that seems to be producing the results that you're looking for. I guess on the call, Dennis you mentioned that based on the
trends and where you're at, fourth quarter could be on track for $1 million or a little bit north of $1 million. It was that accurate? I didn't know if I
heard that correctly, but maybe just summarize that a little bit for me. Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 15, 2023 / 1:30PM, PAVM.OQ - Q3 2023 PAVmed Inc Earnings Call
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay, excellent. Thanks very much. I appreciate it. I'll hop back into the queue.
| 
